1 Executive Summary – Novartis is a Dynamic Healthcare Giant
2 An Overview of Novartis and Its Place in The Global Pharmaceutical Market
2.1 Novartis is a Top 10 Global Pharmaceutical Company With Headquarters in Basel, Switzerland
2.1.1 Mission Statement of the Novartis Group
2.2 A Brief History of Novartis
2.3 The Novartis Pharmaceutical Division Covers A Broad Range of Therapeutic Areas
2.3.1 Cardiovascular & Metabolism
2.3.2 Neuroscience:
2.3.3 Respiratory & Dermatology
2.3.4 ABGHI (Arthritis, bone, gastrointestinal, hormone replacement therapies, urinary incontinence)
2.3.5 Infectious diseases
2.3.6 Oncology & Haematology
2.3.7 Transplantation & Immunology
2.3.8 Ophthalmics
2.3.9 Novartis Is Recognised As Having One Of The Strongest Pharmaceutical Pipelines In The Industry
2.4 Sandoz is a Leading Supplier of Generics Internationally
2.4.1 Sandoz Has A Wide Product Range An Important Core Competencies
2.4.2 Sandoz Finally Benefits from Landmark Regulatory Decision Concerning Omnitrope
2.5 Novartis Consumer Health Holds a Strong Market Position
2.6 Vaccines and Diagnostics from Novartis
2.6.1 New Headquarters for Novartis Vaccines in Cambridge Massachusetts
2.6.2 Novartis Aims To Be First to Use Cell-Culture to Produce Influenza Vaccines
2.6.3 Novartis is Creating Vaccines for a Pandemic Outbreak of Influenza
2.7 Novartis Has Achieved Remarkable Results in Recent Years – Its Growth Was Above The Average For Top 10 Pharmaceutical Companies in 2005
2.8 Novartis Broke Its Own Performance Records In 2006 with 15% Growth Overall
2.8.1 Pharmaceuticals
2.8.2 Consumer Health
2.8.3 Sandoz
2.8.4 Vaccines and Diagnostics
2.9 Novartis Has Performed Very Impressively In Recent Years With Ever-Rising Financial Achievements
3 Novartis Pharmaceuticals Will Continue to Show Marked Gains from 2007-2011
3.1 During 2006, The Pharmaceuticals Division Made Impressive Progress in Key Financial Areas
3.1.1 Sixth Consecutive Year of Growth
3.1.2 Operating Income Expanding Faster Than Net Sales
3.2 Novartis Pharmaceutical Sales Will Exhibit Strong Growth From 2006-2012
3.3 Diovan Was the Leading Product for Novartis in 2006 – The Cardiovascular and Metabolism Portfolio Will Continue to Be Important to the Company from 2007-2012
3.4 Diovan Sales Will Peak in 2010
3.4.1 Diovan is Co-Marketed in Europe
3.4.2 Diovan Led Its Class in 2006
3.4.3 Co-Diovan is a Leading Combination Treatment for Hypertension
3.4.4 Novartis Believes That Diovan Has Potential for Treating Other Conditions
3.4.5 Diovan Has Been Subject to Generic Challenges
3.5 Lotrel Will Show A Gentle Increase in Sales to 2012
3.5.1 Lotrel was the Leader in the ACE inhibitor Class in 2006
3.5.2 Lotrel Also Faced a Generic Challenge
3.6 Lescol
3.6.1 Lescol is a Possible Candidate for an OTC Switch
3.6.2 Lescol Faces Strong Competition in its Class
3.7 Oncology and Haematology
3.8 Gleevec/Glivec
3.8.1 Glivec Competes Well in Its Therapeutic Market Sector
3.8.2 Gleevec/Glivec Has Faced Generic Challenges
3.8.3 Further Clinical Development
3.8.4 Glivec Scheme to Uninsured Patients
3.9 Zometa
3.9.1 Zometa Is Competitive in the Market
3.9.2 Further Developments of the Product
3.9.3 Zometa Awarded Orphan Drug Status in the US
3.9.4 Requirement for Updated Labelling
3.9.5 Postmenopausal Osteoporosis Submission Expected
3.10 Sandostatin (inc. LAR)
3.10.1 Sandostatin Has Lost US Patent Protection and Faces Generic Competition
3.10.2 Sandostatin Has Undergone Life Cycle Management
3.11 Femara
3.11.1 Femara Challenges AstraZeneca’s Nolvadex
3.11.2 Femara Has Received Additional Approval
3.12 Respiratory and Dermatology Revenues
3.13 Lamisil Group
3.13.1 Lamisil Has Been Launched in OTC Form
3.13.2 Continuing Development of Lamisil
3.13.3 Lamisil Led the Systemic Agents for Fungal Infections Class in 2006
3.14 Foradil
3.14.1 Foradil Is a Competitive B-2 Stimulant
3.14.2 Foradil and Collaborations in the Industry
3.14.3 Further Label Warning for Foradil
3.15 Infectious Diseases, Transplantation and Immunology (IDTI)
3.16 Neoral/Sandimmun
3.16.1 Competition is Mounting
3.16.2 Licensing Arrangements
3.16.3 Expansion of Indications
3.17 Famvir
3.17.1 Novartis Acquired Rights from GSK
3.18 Neuroscience
3.19 Trileptal
3.19.1 Trileptal Ranked Number Five in 2006
3.19.2 ANDA Filed for Trileptal
3.19.3 Warnings and Precautions Added to Label
3.20 Voltaren Group
3.20.1 Licensing Deal in Japan
3.21 Exelon
3.21.1 Co-Marketing
3.21.2 Trials With Transdermal Formulation
3.21.3 Exelon Competes With Aricept
3.22 Tegretol
3.22.1 There Are Newer Anti-Epileptics on the Market
3.23 Comtan
3.23.1 Comtan Competes With Novartis’ Stalevo
3.23.2 Orion Licensed Entacapone to Novartis
3.24 Ritalin/Focalin
3.24.1 Ritalin Has Many Strong Competitors
3.24.2 Focalin is a Follow-On Product to Ritalin
3.25 Arthritis/Bone/Gastrointestinal/Urinary (ABGU)
3.26 Zelnorm
3.26.1 Zelmac Leads Class
3.26.2 Novartis Challenges Regulatory Decision
3.26.3 FDA Approval for Chronic Idiopathic Constipation
3.27 Miacalcic
3.27.1 Miacalcic Dominated The 'Calcitonins' Class in 2006
3.27.2 Licensing Deal with Novogyne Pharmaceuticals
3.27.3 Updating of Indications
3.27.4 Further Product Developments
3.28 Ophthalmics
3.28.1 Visudyne
3.28.2 Visudyne is a Strong Contender But Is Susceptible to Off-Label Competition
3.28.3 Verteporfin was discovered at the University of British Columbia
3.28.4 Development Shared Between Novartis and QLT PhotoTherapeutics
3.29 There Has Been and Impressive Rate of New Product Launches by Novartis Recently
3.29.1 Exjade Performed Well in 2006
3.29.2 Xolair is Another Promising New Product
3.29.3 Setback for Elidel
3.30 Novartis Will Successfully Rise to The Challenges of Launching Successful New Products to Replace Mature Drugs from 2007-2012
4 The Market Environment and How Novartis Is Responding To Challenges Facing The Industry
4.1 The World Pharmaceutical Market Continues to Grow, But Faces Mounting Challenges
4.2 The Continuing Success of the Novartis is Dependent Upon Important Drivers and Restraints
4.3 Companies Such As Novartis Are Gradually Changing Their Strategic Focus to Overcome Challenges in the Worldwide Market
4.3.1 Reduced Efficiencies in R&D Result in Concerns Over Thinning Pipelines
4.4 A SWOT Analysis for Novartis, 2007-2012
4.5 Business Strategy in Novartis is Based Upon Three Main Facets
4.6 Novartis Achieved Record Financial Performances in 2006
4.6.1 The Pharmaceuticals Division Provides the Majority of Net Sales in Novartis
4.6.2 Vaccines and Diagnostics Operating Loss of $26m in 2006
4.6.3 Sandoz Operating Income Increased 115% in 2006, with Landmark Approval of Omnitrope – The First Biosimilar to Reach the Market
4.6.4 New Product Launches Are Vital To Novartis’ Continuing Growth and Competitiveness
4.7 Since Its Inception in 1996, Novartis Has Progressively Divested Itself of Non-Healthcare Business Units
4.8 Recent Mergers & Acquisitions by Novartis
4.8.1 Acquisition of Chiron in 2006 Led to Establishment of Vaccines and Diagnostics Division
4.8.2 Acquisition of Hexal and Eon Labs in 2005 Made Sandoz a World Leader in Generics
4.8.3 Strengthening of Sandoz in 2004
4.8.4 From 2002-2003 Novartis Further Expanded Its Portfolio
4.9 Novartis’ International Strategy – Strong Emphasis on Asian Markets, Especially China
4.9.1 US Market Contributes Most Sales
4.9.2 Novartis Is Active in the Japanese Market
4.9.3 Novartis Has Great Deal of Optimism For Growth in China
4.9.4 India is Another Developing Market Prioritised by Novartis
4.10 Novartis Uses Research Alliances Extensively
4.11 Novartis Due to Establish a Strategic Biomedical R&D Centre in Shanghai, China
5 Novartis Consumer Health
5.1 Consumer Health Division Established in 1998
5.2 Solid Results for Consumer Health in 2006
5.3 Steady Growth Expected from 2007-2012 in Consumer Health
5.4 Novartis Sold its Medical Nutrition Business in 2006
6 Novartis Vaccines and Diagnostics
6.1 Novartis Vaccines and Diagnostics is a New Division of Novartis
6.2 Operating Loss of $26m in 2006 for Vaccines and Diagnostics
6.3 Sales Will Increase Strongly As Vaccines and Diagnostics Division Becomes Established in The Novartis Group
6.4 Portfolio Benefits from Increased Strategic Focus
6.5 US Government Contract to Develop Novel Antigen Technology to Increase Vaccine Supplies for Pandemics
6.5.1 Novartis Awarded US Government Contract to Supply Vaccine Against H5N1 Avian Influenza
6.6 Novartis Making Significant Progress In Creating New Strategic Growth Platform In Human Vaccines
6.6.1 Production of H5N1 Influenza Vaccine for Other Countries
6.6.2 Cell Culture-Based Influenza Vaccines Promise Many Advantages
7 Novartis’ Sandoz Generics Division
7.1 Background: Novartis Re-branded Its Generics Companies as Sandoz
7.2 Sandoz Has A Complex History From Establishment in 1886 to Present
7.3 Sandoz Has a Broad Product Range, Much of it Due to Acquisition of Generics Companies
7.4 Retail Generics Produces Finished Dosage Generic Forms
7.5 Sandoz Products: Retail Generics
7.6 Sandoz Products: Contract Biopharmaceuticals
7.7 Sandoz Products: Active Pharmaceutical Ingredients (API)
7.8 Sandoz Products: Product Intermediates
7.9 Sandoz Achieved Impressive Growth in 2006
7.10 Sandoz Will Achieve Strong Growth from 2007-2012
7.11 Sandoz Has Consolidated Its Market Position Through Acquisitions
7.11.1 Sandoz Acquisition Post-Unification: Sabex
7.11.2 Sandoz Acquisitions Post-Unification: Durascan
7.11.3 Novartis Bought Hexal and Eon in $7bn Deal
7.12 Sandoz Receives Landmark US and European Regulatory Approval for Omnitrope in 2006
7.12.1 Sandoz is Committed to The Emerging Field of Biosimilars – Generic Versions of Biopharmaceuticals
7.12.2 Sandoz Filed Lawsuit Against FDA Ruling on Omnitrope
7.12.3 Omnitrope Finally Received US and EU Approval in Early 2006
7.12.4 Omnitrope is a Ground-Breaking Product in the Generics Sector – With Far Reaching Implications for the Market
7.13 Sandoz Invests in Low Cost Production
7.14 The Outlook 2007-2012- Being Part of Novartis Will Confer a Significant Competitive Advantage upon Sandoz
7.14.1 Generics Market is Increasingly Competitive
7.14.2 A Co-ordinated Strategy by Novartis Benefits Sandoz Greatly
7.14.3 Sandoz Will Continue to Gain Prominence in the World Generics Market
8 Pipeline Developments
8.1 Novartis Has Been Very Active in R&D in Recent Years
8.1.1 Key Areas of Development are Oncology and Cardiovascular Diseases
8.1.2 In 2005, Novartis had Five Products Approved/Launched
8.1.3 Developments in Hepatitis C Drugs
8.1.4 Approval and Launch of Five Products in 2005
8.1.5 Important Regulatory Submissions in 2006
8.2 Pipeline Developments: Cardiovascular, 2006
8.2.1 Tekturna (aliskiren/SPP 100)
8.2.2 Exforge
8.2.3 VNP 489
8.3 Oncology/Immunomodulating Agents
8.3.1 Tasigna (nilotinib, AMN 107)
8.3.2 RAD001 (everolimus)
8.3.3 Fingolimod (FTY 720)
8.3.4 Patupilone (EPO 906 or epothilone B)
8.3.5 Vatalanib (PTK/ZK, PTK 787),
8.3.6 Gimatecan (LBQ 707)
8.3.7 LBH 589
8.3.8 AEB 071
8.3.9 Midostaurin (PKC 412),
8.3.10 Pasireotide (SOM 230)
8.3.11 ABJ 879
8.4 Alimentary Tract and Metabolism Agents
8.4.1 Galvus (Vildagliptin/LAF 237)
8.4.2 LBM 642
8.5 Central Nervous System Agents
8.5.1 Agomelatine (AGO 178)
8.5.2 Becampanel (AMP 397)
8.5.3 SAB 378
8.5.4 Emapunil (AC 5216)
8.6 Respiratory System Agents
8.6.1 NVA 237/AD 237
8.6.2 Indacaterol (QAB 149)
8.6.3 TP 10
8.7 Musculoskeletal System Agents
8.7.1 Prexige (lumiracoxib)
8.7.2 ABN 912
8.7.3 ACZ 885
8.7.4 AIN 457
8.8 Sensory Organ Agents/Ophthalmics
8.8.1 Rebamipide (OPC 759)
8.8.2 Lucentis (ranibizumab)
8.9 Systemic Anti-Infective Agents
8.9.1 Mycograb
8.9.2 Albuferon
8.9.3 JE-PIV (IC51)
8.9.4 Aurograb
8.9.5 RSV 604/A 60444
8.9.6 Valopicitabine
8.9.7 Valtorcitabine (LDC 300)
8.10 Novartis Has More Than 100 R&D Alliances With Industry and Academia
9 Conclusions
9.1 Novartis Pharmaceutical Sales Will Exhibit Strong Growth From 2006-2012
9.2 Steady Growth Expected from 2007-2012 in Consumer Health
9.3 Sales Will Increase Strongly As Vaccines and Diagnostics Division Becomes Established in The Novartis Group
9.4 Sandoz Will Achieve Strong Growth from 2007-2012
9.5 The Novartis Group Will Continue to Prosper as Component Divisions Perform Strongly from 2007-2012
9.6 Novartis Benefits from Having One of the Most Promising Pipelines in the Global Pharmaceutical Industry
List of Tables
Table 2.1 Key Events Affecting the Structure and Organisation of Novartis, 2006-Present
Table 2.2 Novartis: Key Product Approvals
Table 2.3 Key Novartis Pharmaceutical Products, 2006
Table 2.4 Top 10 Pharmaceutical Companies: Revenue ($bn), Growth (%) and Share of World Market (%), 12 Months to Q4 2005
Table 2.5 Net Group Sales, Net Group Income and R&D Expenditure ($bn), Including Proportion (%) of Net Sales, 2002-2006
Table 2.6 Net Sales ($m) and Growth (%) by Division, 2005 & 2006
Table 3.1 Novartis Pharmaceuticals Net Sales, Operating Income and R&D, 2005 & 2006 ($m)
Table 3.2 Novartis Pharmaceuticals 2006 International Net Sales (%) by Region, 2005 & 2006
Table 3.3 Novartis Pharmaceuticals Global Net Sales ($m), 2006-2012
Table 3.4 Novartis Pharmaceuticals 6-Year CAGR (%) and Market Share (%), 2006 & 2012
Table 3.5 Novartis Pharmaceuticals Top 20 Products Worldwide Net Sales ($m), 2006
Table 3.6 Novartis Pharmaceutical Products Facing Patent Expiry
Table 3.7 Leading Cardiovascular and Metabolism Revenues ($m), 2006-2012
Table 3.8 Leading Cardiovascular and Metabolism Revenues 6-Year CAGR (%) and Market Share (%), 2006 & 2012
Table 3.9 Leading Oncology and Haematology Revenues ($m), 2006-2012
Table 3.10 Leading Oncology and Haematology Revenues 6-Year CAGR (%) and Market Share (%), 2006 & 2012
Table 3.11 Leading Respiratory and Dermatology Revenues ($m), 2006-2012
Table 3.12 Leading Respiratory and Dermatology Revenues 6-Year CAGR (%) and Market Share (%), 2006 & 2012
Table 3.13 Leading Infectious Diseases, Transplantation and Immunology Revenues ($m), 2006-2012
Table 3.14 Leading Infectious Diseases, Transplantation and Immunology Revenues 6-Year CAGR (%) and Market Share (%), 2006 & 2012
Table 3.15 Leading Neuroscience Revenues ($m), 2006-2012
Table 3.16 Leading Neuroscience Revenues 6-Year CAGR (%) and Market Share (%), 2006 & 2012
Table 3.17 Leading Arthritis/Bone/Gastrointestinal/Urinary (ABGU) Revenues ($m), 2006-2012
Table 3.18 Leading Arthritis/Bone/Gastrointestinal/Urinary Revenues 6-Year CAGR (%) and Market Share (%), 2006 & 2012
Table 3.19 Ophthalmics Revenues ($m), 2006-2012
Table 3.20 Ophthalmics Revenues 6-Year CAGR (%) and Market Share (%), 2006 & 2012
Table 3.21 Novartis Pharmaceuticals Net Sales by Therapeutic Area ($m), 2007-2012
Table 4.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
Table 4.2 A SWOT Chart for Theranostic Applications, 2007-2012
Table 4.3 Key Financials for Novartis Group ($m), 2005 and 2006
Table 4.4 Novartis Group Net Sales ($m) by Division, 2005 and 2006
Table 4.5 Novartis Group Operating Income ($m) by Division, 2006
Table 4.6 Novartis Net Sales and Operating Income – Contribution (%) by Division, 2006
Table 4.7 Share of Novartis Group Sales (%) by Region and Leading Country, June 2005 to June 2006
Table 4.8 Major Developmental Alliances Involving Novartis
Table 5.1 Novartis Consumer Healthcare Net Sales ($m) and Other Key Financials, 2006
Table 5.2 Novartis Consumer Healthcare Continuing Operations Net Sales (%) by Region, 2006
Table 5.3 Continuing vs. Discontinuing Operations Sales (%), 2005 & 2006
Table 5.4 Consumer Health Net Sales ($m), 2006-2012
Table 6.1 Novartis Vaccines & Diagnostics Net Sales ($m) and Other Key Financials, 2006
Table 6.2 Net Sales Before and After Chiron Take-over, 2005 and 2006
Table 6.3 Novartis Vaccines & Diagnostics Net Sales (%) by Region, 2006
Table 6.4 Vaccines and Diagnostics Net Sales ($m), 2006-2012
Table 7.1 Sandoz Net Sales ($m) and Other Key Financials, 2006
Table 7.2 Sandoz Net Sales (%) by Region, 2006
Table 7.3 Sandoz Net Sales ($m), 2006-2012
Table 8.1 Pipeline Developments: Cardiovascular, 2006
Table 8.2 Pipeline Developments: Oncology/Immunomodulating Agents, 2006
Table 8.3 Pipeline Developments: Alimentary Tract and Metabolism, 2006
Table 8.4 Pipeline Developments: Central Nervous System Agents, 2006
Table 8.5 Pipeline Developments: Respiratory System Agents, 2006
Table 8.6 Pipeline Developments: Musculoskeletal System Agents, 2006
Table 8.7 Pipeline Developments: Sensory Organ Agents/Ophthalmics, 2006
Table 8.8 Pipeline Developments: Systemic Anti-Infective Agents, 2006
Table 9.1 Novartis Group Net Sales, 2006-2012
List of Figures
Figure 2.1 Sales for Key Novartis Pharmaceutical Products ($bn), 2006
Figure 2.2 Top 10 Pharmaceutical Revenues ($bn) by Company, 12 Months to Q4 2005
Figure 2.3 Revenue Growth (%) in Top 10 Pharmaceutical Companies, 12 Months to Q4 2005
Figure 2.4 Share of World Market by The Top 10 Pharmaceutical Companies, 12 Months to Q4 2005
Figure 2.5 Net Group Sales, Net Group Income and R&D Expenditure ($bn), 2002-2006
Figure 2.6 Net Group Income and R&D expenditure as a Proportion of Net Group Sales, 2002-2006
Figure 2.7 Net Sales ($m) by Division, 2005 & 2006
Figure 2.8 Net Growth by Division (%), 2005 & 2006
Figure 3.1 Novartis Pharmaceutical Net Sales, Operating Income and R&D Spending ($m), 2005 & 2006
Figure 3.2 Novartis Global Pharmaceutical Net Sales by Region (%), 2006
Figure 3.3 Novartis Pharmaceuticals Overall Net Sales ($m), 2006-2012
Figure 3.4 Top 20 Prescription Products vs. the Rest of the Portfolio (%) Contribution of Revenues, 2006 & 2012
Figure 3.5 Leading Cardiovascular and Metabolism Revenues ($m), 2006-2012
Figure 3.6 Leading Cardiovascular and Metabolism Products: Market Share, 2006 & 2012
Figure 3.7 Divovan Global Revenues ($m), 2006-2012
Figure 3.8 Lotrel Global Revenues ($m), 2006-2012
Figure 3.9 Lescol Global Revenues ($m), 2006-2012
Figure 3.10 Leading Oncology and Haematology Revenues ($m), 2006-2012
Figure 3.11 Leading Oncology and Haematology Products: Market Share (%), 2006 & 2012
Figure 3.12 Gleevec Global Revenues ($m), 2006-2012
Figure 3.13 Zometa Global Revenues ($m), 2006-2012
Figure 3.14 Sandostatin Global Revenues ($m), 2006-2012
Figure 3.15 Femara Global Revenues ($m), 2006-2012
Figure 3.16 Leading Respiratory Revenues ($m), 2006-2012
Figure 3.17 Leading Respiratory Products: Market Share (%), 2006 & 2012
Figure 3.18 Lamisil Global Revenues ($m), 2006-2012
Figure 3.19 Foradil Global Revenues ($m), 2006-2012
Figure 3.20 Leading Infectious Diseases, Transplantation and Immunology Revenues ($m), 2006-2012
Figure 3.21 Leading Infectious Diseases, Transplantation and Immunology Products: Market Share, 2006 & 2012
Figure 3.22 Neoral Global Revenues ($m), 2006-2012
Figure 3.23 Famvir Global Revenues ($m), 2006-2012
Figure 3.24 Neuroscience Revenues ($m), 2006-2012
Figure 3.25 Leading Neuroscience Products: Market Share (%), 2006 & 2012
Figure 3.26 Trileptal Global Revenues ($m), 2006-2012
Figure 3.27 Voltaren Global Revenues ($m), 2006-2012
Figure 3.28 Exelon Global Revenues ($m), 2006-2012
Figure 3.29 Tegretol Global Revenues ($m), 2006-2012
Figure 3.30 Comtan Global Revenues ($m), 2006-2012
Figure 3.31 Ritalin/Focalin Global Revenues ($m), 2006-2012
Figure 3.32 Leading Arthritis/Bone/Gastrointestinal/Urinary Revenues ($m), 2006-2012
Figure 3.33 Leading Arthritis/Bone/Gastrointestinal/Urinary Products: Market Share (%), 2006 & 2012
Figure 3.34 Zelnorm Global Revenues ($m), 2006-2012
Figure 3.35 Miacalcic Global Revenues ($m), 2006-2012
Figure 3.36 Ophthalmics Revenues ($m), 2006-2012
Figure 3.37 Ophthalmics Products: Market Share (%), 2006 & 2012
Figure 3.38 Visudyne Global Revenues ($m), 2006-2012
Figure 3.39 Novartis Pharmaceuticals Net Sales by Therapeutic Area ($m), 2007-2012
Figure 4.1 Revenue Generation ($bn) by the World Pharmaceutical Industry, 1999-2005
Figure 4.2 Key Financials for Novartis Group ($m), 2005 and 2006
Figure 4.3 Novartis Group Net Sales ($m) by Division, 2006
Figure 4.4 Novartis Group Operating Income ($m) by Division 2006
Figure 4.5 Novartis Net Sales – Contribution (%) by Division, 2006
Figure 4.6 Novartis Operating Income – Contribution (%) by Division, 2006
Figure 5.1 Novartis Consumer Healthcare Net Sales ($m), 2006
Figure 5.2 Novartis Consumer Healthcare Continuing Operations Net Sales (%) by Region, 2006
Figure 5.3 Continuing vs. Discontinuing Operations Sales (%), 2005 & 2006
Figure 5.4 Consumer Health Net Sales ($m), 2006-2012
Figure 6.1 Novartis Vaccines & Diagnostics Net Sales ($m) and Other Key Financials, 2006
Figure 6.2 Novartis Vaccines & Diagnostics Net Sales (%) by Region, 2006
Figure 6.3 Vaccines and Diagnostics Net Sales ($m), 2006-2012
Figure 7.1 Sandoz Net Sales ($m) and Other Key Financials, 2006
Figure 7.2 Sandoz Net Sales (%) by Region, 2006
Figure 7.3 Sandoz Net Sales ($m), 2006-2012
Figure 9.1 Novartis Group Net Sales, 2006-2012